Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study

Basit Öğe Kaydı
dc.authorid0000-0002-6388-0346
dc.authorid0000-0002-0631-4006
dc.authorid0000-0003-1998-3150
dc.authorid0000-0001-7399-2360
dc.authorid0000-0001-5790-7066
dc.authorscopusid57195539645
dc.authorscopusid57193238894
dc.authorscopusid57211890516
dc.authorscopusid57202946758
dc.authorscopusid57205608177
dc.authorscopusid57185674600
dc.authorscopusid57205578251
dc.authorwosidAvcı, Okan/ABG-8782-2021
dc.contributor.authorCil, İbrahim
dc.contributor.authorKücükarda, Ahmet
dc.contributor.authorAtci, Muhammed Mustafa
dc.contributor.authorSecmeler, Saban
dc.contributor.authorPaksoy, Nail
dc.contributor.authorFerhatoglu, Ferhat
dc.contributor.authorAydiner, Adnan
dc.contributor.authorAvcı, Okan
dc.date.accessioned2022-05-11T14:40:57Z
dc.date.available2022-05-11T14:40:57Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractIntroduction: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, clinical trials underrepresent patients > 65 years of age, leading to a lack of information in this population. We analyzed the real-world outcomes of older women who were treated with T-DM1 therapy. Methods: We performed a multicenter, observational, retrospective analysis of patients aged > 65 years treated with T-DM1. A total of 93 patients from 10 cancer centers were involved in the study. Our goal was to determine the survival, response rates, and toxicity profile in T-DM1-treated patients, as well as the factors that influence survival. Results: Median follow-up was 12.2 months. Objective response rate was 29%. Median progression-free survival (PFS) and overall survival (OS) were 8.47 and 15.0 months, respectively. In multivariate analysis, Eastern Cooperative Oncology Group Performance Score 2 was found to be an independent prognostic factor for worse PFS (hazard ratio [HR] 1.81, p = 0.032) and OS (HR 2.33, p = 0.006). Any adverse event (AE) was seen in 92.5% of patients; grade 3 or 4 AEs were seen in 30.1%. Dose reduction or treatment discontinuation rates were 11.8% and 6.5%, respectively. Conclusion: The efficacy of T-DM1 was acceptable and it was generally well-tolerated among older patients with advanced HER2-positive breast cancer.
dc.identifier.doi10.1177/03008916211037739
dc.identifier.endpage25
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue1en_US
dc.identifier.pmid34365852
dc.identifier.scopus2-s2.0-85112296856
dc.identifier.scopusqualityQ3
dc.identifier.startpage19
dc.identifier.urihttps://doi.org/10.1177/03008916211037739
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8988
dc.identifier.volume108
dc.identifier.wosWOS:000685650500001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAvcı, Okan
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofTumori Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHER2 positive
dc.subjectmetastatic breast cancer
dc.subjectolder patients
dc.subjectreal-world
dc.subjectPhysiological-Aspects
dc.subjectDecision-Making
dc.subjectAge
dc.subjectManagement
dc.subjectSurvival
dc.subjectImpact
dc.subjectT-Dm1
dc.subjectWomen
dc.titleEfficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu